Cargando…
2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatiktam Kashayam against COVID-19: an in silico and in vitro approach
Nimbamritadi Panchatiktam Kashayam (NPK) is an ayurvedic formulation composed of ingredients with potent anti-viral activities. We studied the interaction energy of 144 phytoconstituents present in NPK against spike receptor-binding domain (RBD) complexed with ACE2 protein (PDB ID: 6LZG) and RNA-dep...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648999/ https://www.ncbi.nlm.nih.gov/pubmed/36357813 http://dx.doi.org/10.1007/s11030-022-10552-z |
_version_ | 1784827704203280384 |
---|---|
author | Murali, Maneesha Nair, Bhagyalakshmi Vishnu, V. R. Aneesh, T. P. Nath, Lekshmi R. |
author_facet | Murali, Maneesha Nair, Bhagyalakshmi Vishnu, V. R. Aneesh, T. P. Nath, Lekshmi R. |
author_sort | Murali, Maneesha |
collection | PubMed |
description | Nimbamritadi Panchatiktam Kashayam (NPK) is an ayurvedic formulation composed of ingredients with potent anti-viral activities. We studied the interaction energy of 144 phytoconstituents present in NPK against spike receptor-binding domain (RBD) complexed with ACE2 protein (PDB ID: 6LZG) and RNA-dependent RNA polymerase protein (PDB ID: 7BTF) using Biovia Drug Discovery studio. The result indicated that 2,4-hydroxycinnamic acid exerts more significant binding affinities (28.43 kcal/mol) than Umifenovir (21.24 kcal/mol) against spike ACE2. Apigenin exhibited the highest binding affinities (54.63 kcal/mol) compared with Remdesivir (24.52 kcal/mol) against RdRp. An in vitro analysis showed a reduction in the number of lentiviral particles on transfected HEK293T-hACE2 cells as assessed by pseudovirus inhibition assay. At the same time, the tested compounds showed non-toxic up to 100 µg/ml in normal cells by MTT assay. The study highlights the plausible clinical utility of this traditional medicine against SARS CoV2. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11030-022-10552-z. |
format | Online Article Text |
id | pubmed-9648999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-96489992022-11-14 2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatiktam Kashayam against COVID-19: an in silico and in vitro approach Murali, Maneesha Nair, Bhagyalakshmi Vishnu, V. R. Aneesh, T. P. Nath, Lekshmi R. Mol Divers Short Communication Nimbamritadi Panchatiktam Kashayam (NPK) is an ayurvedic formulation composed of ingredients with potent anti-viral activities. We studied the interaction energy of 144 phytoconstituents present in NPK against spike receptor-binding domain (RBD) complexed with ACE2 protein (PDB ID: 6LZG) and RNA-dependent RNA polymerase protein (PDB ID: 7BTF) using Biovia Drug Discovery studio. The result indicated that 2,4-hydroxycinnamic acid exerts more significant binding affinities (28.43 kcal/mol) than Umifenovir (21.24 kcal/mol) against spike ACE2. Apigenin exhibited the highest binding affinities (54.63 kcal/mol) compared with Remdesivir (24.52 kcal/mol) against RdRp. An in vitro analysis showed a reduction in the number of lentiviral particles on transfected HEK293T-hACE2 cells as assessed by pseudovirus inhibition assay. At the same time, the tested compounds showed non-toxic up to 100 µg/ml in normal cells by MTT assay. The study highlights the plausible clinical utility of this traditional medicine against SARS CoV2. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11030-022-10552-z. Springer International Publishing 2022-11-10 /pmc/articles/PMC9648999/ /pubmed/36357813 http://dx.doi.org/10.1007/s11030-022-10552-z Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Short Communication Murali, Maneesha Nair, Bhagyalakshmi Vishnu, V. R. Aneesh, T. P. Nath, Lekshmi R. 2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatiktam Kashayam against COVID-19: an in silico and in vitro approach |
title | 2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatiktam Kashayam against COVID-19: an in silico and in vitro approach |
title_full | 2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatiktam Kashayam against COVID-19: an in silico and in vitro approach |
title_fullStr | 2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatiktam Kashayam against COVID-19: an in silico and in vitro approach |
title_full_unstemmed | 2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatiktam Kashayam against COVID-19: an in silico and in vitro approach |
title_short | 2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatiktam Kashayam against COVID-19: an in silico and in vitro approach |
title_sort | 2,4-dihydroxycinnamic acid as spike ace2 inhibitor and apigenin as rdrp inhibitor in nimbamritadi panchatiktam kashayam against covid-19: an in silico and in vitro approach |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648999/ https://www.ncbi.nlm.nih.gov/pubmed/36357813 http://dx.doi.org/10.1007/s11030-022-10552-z |
work_keys_str_mv | AT muralimaneesha 24dihydroxycinnamicacidasspikeace2inhibitorandapigeninasrdrpinhibitorinnimbamritadipanchatiktamkashayamagainstcovid19aninsilicoandinvitroapproach AT nairbhagyalakshmi 24dihydroxycinnamicacidasspikeace2inhibitorandapigeninasrdrpinhibitorinnimbamritadipanchatiktamkashayamagainstcovid19aninsilicoandinvitroapproach AT vishnuvr 24dihydroxycinnamicacidasspikeace2inhibitorandapigeninasrdrpinhibitorinnimbamritadipanchatiktamkashayamagainstcovid19aninsilicoandinvitroapproach AT aneeshtp 24dihydroxycinnamicacidasspikeace2inhibitorandapigeninasrdrpinhibitorinnimbamritadipanchatiktamkashayamagainstcovid19aninsilicoandinvitroapproach AT nathlekshmir 24dihydroxycinnamicacidasspikeace2inhibitorandapigeninasrdrpinhibitorinnimbamritadipanchatiktamkashayamagainstcovid19aninsilicoandinvitroapproach |